How people with narcolepsy or idiopathic hypersomnia think socially

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study compares social cognition in adults with narcolepsy (types 1 and 2) or idiopathic hypersomnia to understand how these conditions may affect social understanding and interactions. Participants complete a questionnaire to assess social cognitive skills. The study aims to provide insight into whether narcolepsy and hypersomnia influence social functioning beyond daytime sleepiness. It is conducted at CHU Amiens-Picardie with no active comparator and relies on self-reported measures. The findings could inform supportive strategies to improve social participation for affected individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult patients (\>/= 18years old)
* diagnosis of type 1 or type 2 narcolepsy or idiopathic hypersomnia
* non opposition

Exclusion Criteria:

* comorbid psychiatric or neurologic disease
* patient under 18 years old
* patient under guardianship, curators or deprived of liberty, refusal of the patient

Where it's running

• CHU Amiens-Picardie
  Amiens, France Recruiting

Study contacts

• Study coordinator: Mathilde FLAMAND, MD
• Email: Flamand.mathilde@chu-amiens.fr
• Phone: 0322455959

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Parent-Mediated Social-Cognition Intervention for Young Children with Autism

  This study tests a parent-led, home-based play program to help young children with autism improve social-cognition skills.

  Recruiting Children's Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07708246

• HBS-301 for Narcolepsy: daily wakefulness and sleepiness improvement in adults

  This Phase 3 study tests HBS-301 vs placebo in adults with narcolepsy to see if it helps with daytime sleepiness, cataplexy, sleepiness, and fatigue.

  Recruiting at 29 sites Phase 3 Harmony Biosciences Management, Inc. · Birmingham, Alabama and 52 other locations · NCT07675135

• Expanded-dosing Xywav vs placebo in narcolepsy and IH

  This study tests whether expanded nightly dosing of Xywav helps adults with narcolepsy or idiopathic hypersomnia, compared with placebo.

  Recruiting at 15 sites Phase 3 Jazz Pharmaceuticals · Birmingham, Alabama and 14 other locations · NCT07625280

• Testing Lu AH69593 for safety and tolerance in healthy adults and people with narcolepsy

  This study tests whether Lu AH69593 is safe and well tolerated in adults, including those with narcolepsy, and looks at how the body processes the drug with and without food.

  Recruiting Phase 1 H. Lundbeck A/S · Helsinki and 1 other locations · NCT07613710

• Samelisant for Narcolepsy: A Phase 3 Test for EDS and Cataplexy

  This phase 3 study tests whether Samelisant can reduce daytime sleepiness and cataplexy in adults with narcolepsy.

  Recruiting Phase 3 Suven Life Sciences Limited · Columbia, South Carolina · NCT07540364

• E2086 for adults with narcolepsy: find the best dose compared with placebo

  This study tests different doses of E2086 against placebo in adults with narcolepsy to see if it reduces daytime sleepiness.

  Recruiting at 2 sites Phase 2 Eisai Inc. · Santa Ana, California and 56 other locations · NCT07493265

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.